Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > BNN Coverage of New CEO
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by smallshorton Nov 02, 2016 4:49pm
63 Views
Post# 25417987

RE:RE:RE:RE:RE:BNN Coverage of New CEO

RE:RE:RE:RE:RE:BNN Coverage of New CEO
DeathPool wrote:
What you have stated on drug pricing practices in the UK is inaccurate.  You should not make statements on drug pricing without an examination of NHS Prescription Cost Analysis.  Veritas Research has done an extensive analysis of AMCo's Key Drugs Levothyroxine Sodium, Nitrofurantoin, Prednisolone, Carbimazole, Liothyronine (*mentioned specifically in the House of Common by a member of parliament), Fusidic Acid, Erythromycin, Co-Cadamol and Tanylcypromine Sulfate.  Shorts have a directional sence of what the porfolio looks like, and I doubt many are covering their position before Q3.  Good luck.
Excellent info!  I agree.  I don't think the large US based short sellers are covering here.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested